Impact BioMedical Inc. (IBO) Financial Ratios
8 years of historical data (2017–2024) · Healthcare · Biotechnology
EV/EBITDA
226.79
↓-41% vs avg
5yr avg: 384.31
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
27.10
↓-42% vs avg
5yr avg: 46.58
30Y Low46.6·High46.6
ROE
↑
-11.6%
↓+97% vs avg
5yr avg: -355.4%
30Y Low-404%·High-12%
Debt/EBITDA
9.92
+0% vs avg
5yr avg: 9.92
30Y Low9.9·High9.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IBO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Impact BioMedical Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $144M | $337M | — | — | — | — | — | — | $254M |
| Enterprise Value | $149M | $344M | — | — | — | — | — | — | $254M |
| P/E Ratio → | -84.36 | — | — | — | — | — | — | — | — |
| P/S Ratio | 84.14 | 144.63 | — | — | — | — | — | — | — |
| P/B Ratio | 27.10 | 46.58 | — | — | — | — | — | — | 859.87 |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IBO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Impact BioMedical Inc.'s enterprise value stands at 226.8x EBITDA, 41% below its 5-year average of 384.3x. The Healthcare sector median is 14.4x, placing the stock at a 1476% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 147.58 | — | — | — | — | — | — | — |
| EV / EBITDA | 226.79 | 384.31 | — | — | — | — | — | — | 1127.54 |
| EV / EBIT | 367.99 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
IBO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Impact BioMedical Inc. earns an operating margin of 23.7%. Operating margins have expanded from -6808.0% to 23.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -11.6% indicates the company is currently destroying shareholder equity. ROIC of 1.5% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | 23.7% | 23.7% | — | -6808.0% | -6808.0% | — | — | — | — |
| Net Profit Margin | -88.0% | -88.0% | — | -14102.0% | -14102.0% | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -11.6% | -11.6% | -14.2% | -19.4% | -35.3% | -1696.4% | -404.2% | -39.9% | -138.3% |
| ROA | -6.3% | -6.3% | -9.5% | -13.7% | -25.0% | -802.8% | -353.5% | -36.5% | -127.3% |
| ROIC | 1.5% | 1.5% | -7.3% | -5.4% | -9.7% | -33156.1% | — | -21.6% | — |
| ROCE | 2.6% | 2.6% | -12.0% | -8.5% | -15.5% | -1525.3% | -465.8% | -13.8% | 21.7% |
IBO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Impact BioMedical Inc. carries a Debt/EBITDA ratio of 9.9x, which is highly leveraged (201% above the sector average of 3.3x). Net debt stands at $7M ($9M total debt minus $2M cash). Interest coverage of 3.3x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.23 | 1.23 | 0.43 | 0.31 | 0.31 | — | — | — | — |
| Debt / EBITDA | 9.92 | 9.92 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.95 | 0.43 | 0.31 | 0.31 | — | -1.03 | -1.04 | -0.18 |
| Net Debt / EBITDA | 7.68 | 7.68 | — | — | — | — | — | -1.49 | -0.23 |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 3.27 | 3.27 | -9.07 | -7.37 | -7.37 | — | — | — | — |
IBO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.25x is below 1.0, meaning current liabilities exceed current assets. The current ratio has improved from 0.01x to 0.25x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.25 | 0.25 | 0.03 | 0.01 | 0.02 | 3.98 | 5.31 | 10.81 | 12.61 |
| Quick Ratio | 0.25 | 0.25 | 0.03 | 0.01 | 0.02 | 3.98 | 5.31 | 10.81 | 12.61 |
| Cash Ratio | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 | 2.89 | 4.50 | 10.20 | 2.04 |
| Asset Turnover | — | 0.11 | — | 0.00 | 0.00 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 28.81 | — | 116.80 | 1438.10 | — | — | — | — |
IBO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Impact BioMedical Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — | — | 0.0% |
| Shares Outstanding | — | $233M | $191M | $11M | $60M | $70496 | $12M | $10M | $10M |
Peer Comparison
Compare IBO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IBOYou | $144M | -84.4 | 226.8 | — | 100.0% | 23.7% | -11.6% | 1.5% | 9.9 |
 NNVC | $31M | -2.3 | — | — | — | — | -99.7% | -114.0% | — |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 VXRT | $178M | 10.6 | 7.4 | 23.5 | — | 7.6% | 22.3% | 27.1% | 0.5 |
 OCGN | $487M | -6.3 | — | — | 45.9% | -1425.7% | -776.9% | -1565.6% | — |
 ADMA | $2B | 14.1 | 10.1 | 73.1 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 ICLR | $10B | 13.1 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 MEDP | $12B | 28.1 | 21.3 | 18.0 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See IBO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IBO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IBO vs NNVC
Side-by-side business, growth, and profitability comparison vs NanoViricides, Inc..
Start ComparisonIBO — Frequently Asked Questions
Quick answers to the most common questions about buying IBO stock.
What is Impact BioMedical Inc.'s P/E ratio?
Impact BioMedical Inc.'s current P/E ratio is -84.4x. This places it at the 50th percentile of its historical range.
What is Impact BioMedical Inc.'s EV/EBITDA?
Impact BioMedical Inc.'s current EV/EBITDA is 226.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
What is Impact BioMedical Inc.'s ROE?
Impact BioMedical Inc.'s return on equity (ROE) is -11.6%. The historical average is -94.7%.
Is IBO stock overvalued?
Based on historical data, Impact BioMedical Inc. is trading at a P/E of -84.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Impact BioMedical Inc.'s profit margins?
Impact BioMedical Inc. has 100.0% gross margin and 23.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Impact BioMedical Inc. have?
Impact BioMedical Inc.'s Debt/EBITDA ratio is 9.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.